VNA-318
Cognitive Impairment (Alzheimer's Disease, Major Depressive Disorder)
Key Facts
About Vandria
Vandria is a private, clinical-stage biotechnology company pioneering a novel approach to age-related diseases by targeting mitochondrial dysfunction and inflammation. Its lead asset, VNA-318, is an oral, brain-penetrant small molecule that has completed Phase I studies, showing safety and target engagement for potential use in Alzheimer's disease and other CNS conditions. The company has raised $32M in venture funding from notable investors like ND Capital and Hevolution Foundation and is building a pipeline across CNS, muscle, lung, and liver diseases. With an experienced leadership team and a first-in-class mechanism, Vandria aims to develop disease-modifying therapies for major unmet medical needs.
View full company profile